283 related articles for article (PubMed ID: 26257206)
1. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.
Fitzgerald TL; Lertpiriyapong K; Cocco L; Martelli AM; Libra M; Candido S; Montalto G; Cervello M; Steelman L; Abrams SL; McCubrey JA
Adv Biol Regul; 2015 Sep; 59():65-81. PubMed ID: 26257206
[TBL] [Abstract][Full Text] [Related]
2. Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells.
Lee S; Heinrich EL; Lu J; Lee W; Choi AH; Luu C; Chung V; Fakih M; Kim J
Pancreas; 2016 Feb; 45(2):286-92. PubMed ID: 26262587
[TBL] [Abstract][Full Text] [Related]
3. Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells.
McCubrey JA; Fitzgerald TL; Yang LV; Lertpiriyapong K; Steelman LS; Abrams SL; Montalto G; Cervello M; Neri LM; Cocco L; Martelli AM; Laidler P; Dulińska-Litewka J; Rakus D; Gizak A; Nicoletti F; Falzone L; Candido S; Libra M
Oncotarget; 2017 Feb; 8(8):14221-14250. PubMed ID: 27999207
[TBL] [Abstract][Full Text] [Related]
4. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
5. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.
McCubrey JA; Meher AK; Akula SM; Abrams SL; Steelman LS; LaHair MM; Franklin RA; Martelli AM; Ratti S; Cocco L; Barbaro F; Duda P; Gizak A
Aging (Albany NY); 2022 Apr; 14(8):3365-3386. PubMed ID: 35477123
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
Brechbiel J; Miller-Moslin K; Adjei AA
Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
[TBL] [Abstract][Full Text] [Related]
7. GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.
Bang D; Wilson W; Ryan M; Yeh JJ; Baldwin AS
Cancer Discov; 2013 Jun; 3(6):690-703. PubMed ID: 23547054
[TBL] [Abstract][Full Text] [Related]
8. Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer.
McCubrey JA; Rakus D; Gizak A; Steelman LS; Abrams SL; Lertpiriyapong K; Fitzgerald TL; Yang LV; Montalto G; Cervello M; Libra M; Nicoletti F; Scalisi A; Torino F; Fenga C; Neri LM; Marmiroli S; Cocco L; Martelli AM
Biochim Biophys Acta; 2016 Dec; 1863(12):2942-2976. PubMed ID: 27612668
[TBL] [Abstract][Full Text] [Related]
9. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
10. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
11. Molecular targeting therapy for pancreatic cancer.
Xiong HQ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S69-77. PubMed ID: 15316751
[TBL] [Abstract][Full Text] [Related]
12. Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy.
Steelman LS; Fitzgerald T; Lertpiriyapong K; Cocco L; Follo MY; Martelli AM; Neri LM; Marmiroli S; Libra M; Candido S; Nicoletti F; Scalisi A; Fenga C; Drobot L; Rakus D; Gizak A; Laidler P; Dulinska-Litewka J; Basecke J; Mijatovic S; Maksimovic-Ivanic D; Montalto G; Cervello M; Milella M; Tafuri A; Demidenko Z; Abrams SL; McCubrey JA
Curr Pharm Des; 2016; 22(16):2358-88. PubMed ID: 26947958
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
14. A new alpha in line between KRAS and NF-κB activation?
Pak C; Miyamoto S
Cancer Discov; 2013 Jun; 3(6):613-5. PubMed ID: 23749528
[TBL] [Abstract][Full Text] [Related]
15. Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer.
Zhu Z; Xiao S; Hao H; Hou Q; Fu X
Curr Top Med Chem; 2019; 19(23):2176-2186. PubMed ID: 31456520
[TBL] [Abstract][Full Text] [Related]
16. Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.
Brauswetter D; Gurbi B; Varga A; Várkondi E; Schwab R; Bánhegyi G; Fábián O; Kéri G; Vályi-Nagy I; Peták I
PLoS One; 2017; 12(9):e0185687. PubMed ID: 28957417
[TBL] [Abstract][Full Text] [Related]
17. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-A connection to licensing nodes.
Schneeweis C; Wirth M; Saur D; Reichert M; Schneider G
Small GTPases; 2018 Nov; 9(6):457-464. PubMed ID: 27880072
[TBL] [Abstract][Full Text] [Related]
19. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer.
Kang R; Hou W; Zhang Q; Chen R; Lee YJ; Bartlett DL; Lotze MT; Tang D; Zeh HJ
Cell Death Dis; 2014 Oct; 5(10):e1480. PubMed ID: 25341034
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic Cancer Stem Cells and Therapeutic Approaches.
Ercan G; Karlitepe A; Ozpolat B
Anticancer Res; 2017 Jun; 37(6):2761-2775. PubMed ID: 28551612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
